



# HHS Public Access

Author manuscript

JAMA Pediatr. Author manuscript; available in PMC 2015 April 01.

Published in final edited form as:

JAMA Pediatr. 2014 April ; 168(4): 381–383. doi:10.1001/jamapediatrics.2013.4531.

## CD4 Counts of Nonperinatally HIV–Infected Youth and Young Adults Presenting for HIV Care Between 2002 and 2010

Allison L. Agwu, MD, ScM, Asha Neptune, MA, MPH, Cindy Voss, MA, Baligh Yehia, MD, MPP, MSHP, and Richard Rutstein, MD for the HIV Research Network

Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland (Agwu); Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland (Agwu, Voss); Howard University College of Medicine, Washington, DC (Neptune); Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Yehia); Division of General Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania (Rutstein)

---

Human immunodeficiency virus (HIV) incidence is increasing among youth, particularly young men who have sex with men and racial/ethnic minorities. Earlier presentation to care, a goal of public health initiatives, can limit immune deterioration and HIV transmission. We determined if fewer nonperinatally HIV (nPHIV)–infected youth are presenting for care at lower CD4 counts.

### Methods

This was a retrospective study of nPHIV-infected 12- to 24-year-olds presenting for care at HIV Research Network (HIVRN) sites between 2002 and 2010.<sup>1</sup> The 13 geographically distributed sites that contributed data over the study period all had institutional review board approval for the study (from Alameda County Medical Center, Children’s Hospital of Philadelphia, Community Health Network, Drexel University, Johns Hopkins University, Montefiore Medical Group, Montefiore Medical Center, Oregon Health and Science University, Parkland Health and Hospital System, St. Jude’s Children’s Hospital and

---

Copyright 2014 American Medical Association. All rights reserved.

Corresponding Author: Allison L. Agwu, MD, ScM, 200 N Wolfe St, Room 3145, Baltimore, MD 21287 (ageorg10@jhmi.edu).

**Conflict of Interest Disclosures:** None reported.

**Publisher’s Disclaimer: Disclaimer:** The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the Agency for Healthcare Research and Quality is intended or should be inferred.

**Author Contributions:** Dr Agwu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Study concept and design:* Agwu, Yehia, Rutstein.

*Acquisition of data:* Voss.

*Analysis and interpretation of data:* Agwu, Neptune, Yehia.

*Drafting of the manuscript:* Agwu, Neptune, Voss.

*Critical revision of the manuscript for important intellectual content:* Agwu, Neptune, Yehia, Rutstein.

*Statistical analysis:* Agwu, Neptune.

*Obtained funding:* Agwu.

*Administrative, technical, or material support:* Voss, Yehia.

*Study supervision:* Agwu.

University of Tennessee, St. Luke's Roosevelt Hospital Center, Tampa General Health Care, University of California, San Diego, and Wayne State University). Eligible patients, who provided informed consent (oral or written depending on the rules of the approving institutional review board), had at least 1 CD4 value and were antiretroviral therapy naive. To assure exclusion of patients who received care previously, we excluded patients whose first recorded HIV-1 RNA level was less than the limit of detection of the used assay or less than 2.6 log<sub>10</sub> HIV-1 RNA copies/mL (n = 174); patients whose first CD4 or HIV-1 RNA measurement preceded clinic enrollment by more than 45 days (n = 200); and those with incomplete data (n = 2; unable to rule out prior antiretroviral therapy). The primary outcome was a presenting CD4 count less than 350 cells/mm<sup>3</sup>. Multivariate logistic regression assessed demographic and clinical factors associated with the outcome. Given the large proportion of males, we also conducted a male-only subgroup analysis.

## Results

One thousand four hundred ninety-seven nPHIV-infected 12- to 24-year-old youth presented to care at HIVRN sites (Table 1). The proportion with a presenting CD4 count less than 350 cells/mm<sup>3</sup> remained between 30% and 45% over the study period (*P* trend >.05). Black race (adjusted odds ratio [AOR], 2.03 [95% CI, 1.31–3.15]), Hispanic ethnicity (AOR, 1.69 [95% CI, 1.21–2.34]), male gender (AOR, 1.63 [95% CI, 1.16–2.30]), heterosexual acquisition risk (AOR, 1.43 [95% CI, 1.08–1.88]), higher HIV-1 RNA level, and increasing age (AOR, 1.14 [95% CI, 1.06–1.23]) were independently associated with a greater likelihood of a presenting CD4 count less than 350 cells/mm<sup>3</sup> (Table 2). These findings remained consistent in the male-only subgroup analysis (Table 3).

## Discussion

Between 2002 and 2010, there was no overall improvement in presenting CD4 count among nPHIV-infected youth at HIVRN sites, contrary to data in adults.<sup>2,3</sup> The trend in youth may be related to continued risk behaviors in this population related to developmental and cognitive stage, in addition to testing and engagement challenges. As in adults, racial/ethnic minority status is associated with lower presenting CD4 count among youth, particularly young men who have sex with men, a population at the forefront of the youth epidemic. While recent data show improvements in racial/ethnic disparities in adults,<sup>3</sup> our data demonstrate no apparent improvement over the past decade for youth. The gender disparity among youth is opposite to that in adults.<sup>2,3</sup>

Female youth may access health care more frequently than males, in part because of reproductive and gynecologic/obstetric needs,<sup>4</sup> which may increase opportunities for HIV testing and linkage to care. More effective methods to recruit at-risk male youth into early testing and linkage to care are needed.

Heterosexual acquisition was also associated with an increased likelihood of presenting with a CD4 count less than 350 cells/mm<sup>3</sup>, highlighting a potential gap in outreach efforts because they may engage in high risk behaviors and not perceive that they are at risk and thereby test and present for care later.<sup>5</sup> Lastly, higher HIV-1 RNA level, which increases

risk of progression to AIDS, was associated with a presenting CD4 count less than 350 cells/mm<sup>3</sup>. Of concern is that significant proportions of youth, who often continue to engage in high-risk behaviors,<sup>6</sup> had high HIV-1 RNA levels, increasing HIV transmission risk.

The study has some limitations. Socioeconomic data are not collected by HIVRN, and mental health and substance abuse data are incomplete and were not evaluated. A limited number of 12- to 16-year-olds, injection drug users, or heterosexual males were in the cohort. Last, some patients may have presented for care previously at other sites.

## Conclusions

The proportion of nPHIV-infected youth presenting to HIVRN sites with a CD4 count less than 350 cells/mm<sup>3</sup> remained essentially unchanged between 2002 and 2010. Minority, male, and heterosexual youth may warrant innovative strategies to target these populations.

## Acknowledgments

**Funding/Support:** This study was supported by Agency for Healthcare Research and Quality grant 290-01-0012 and Health Resources and Services Administration contract HHS250201200008C. Dr Agwu was supported by National Institutes of Allergy and Infectious Diseases grant 1K23 AI084549 and a Ross Clinician Scientist Award. Ms Neptune was supported by the James A. Ferguson Emerging Infectious Diseases Fellowship (5U50MN000025-02). Dr Yehia was supported by National Institutes of Health grant K23-MH-097647-01A1.

**Role of the Sponsor:** The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

## References

1. [Accessed August 15, 2013] HIV Research Network website. <https://cde.johnshopkins.edu/hivrn/index.cfm>
2. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis*. 2010; 50(11):1512–1520. [PubMed: 20415573]
3. Haines, C.; Fleishman, JA.; Bamford, L.; Gebo, K. The CD4 count of newly presenting patients increased after HIV screening guidelines changed. Paper presented at: Infectious Diseases Society of America; October 2012; San Diego, CA. Abstract 122
4. Rand CM, Shone LP, Albertin C, Auinger P, Klein JD, Szilagyi PG. National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. *Arch Pediatr Adolesc Med*. 2007; 161(3):252–259. [PubMed: 17339506]
5. O'Sullivan LFU, Udell W, Patel VL. Young urban adults' heterosexual risk encounters and perceived risk and safety: a structured diary study. *J Sex Res*. 2006; 43(4):343–351. [PubMed: 17599255]
6. Trent M, Chung SE, Ellen JM, Clum G. Adolescent HIV/AIDS Trials Network. New sexually transmitted infections among adolescent girls infected with HIV. *Sex Transm Infect*. 2007; 83(6): 468–469. [PubMed: 17699560]

## Group Information

HIV Research Network participating sites and principal investigators: Alameda County Medical Center, Oakland, California: Howard Edelstein, MD; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania: Richard Rutstein, MD; Community Health Network, Rochester, New York: Roberto Corales, DO; Drexel University, Philadelphia,

Pennsylvania: Jeffrey Jacobson, MD, Sara Allen, CRNP; Johns Hopkins University, Baltimore, Maryland: Kelly Gebo, MD, Richard Moore, MD, Allison Agwu, MD; Montefiore Medical Group, Bronx, New York: Robert Beil, MD; Montefiore Medical Center, Bronx, New York: Lawrence Hanau, MD; Oregon Health and Science University, Portland: P. Todd Korthuis, MD; Parkland Health and Hospital System, Dallas, Texas: Ank Nijhawan, MD, Muhammad Akbar, MD; St. Jude’s Children’s Hospital and University of Tennessee, Memphis: Aditya Gaur, MD; St. Luke’s Roosevelt Hospital Center, New York, New York: Victoria Sharp, MD, Stephen Arpadi, MD; Tampa General Health Care, Tampa, Florida: Charurut Somboonwit, MD; University of California, San Diego: W. Christopher Mathews, MD; Wayne State University, Detroit, Michigan: Jonathan Cohn, MD. Sponsoring agencies: Agency for Healthcare Research and Quality, Rockville, Maryland: Fred Hellinger, PhD, John Fleishman, PhD, Irene Fraser, PhD; Health Resources and Services Administration, Rockville, Maryland: Robert Mills, PhD, Faye Malitz, MS. Data Coordinating Center: Johns Hopkins University: Richard Moore, MD, Jeanne Keruly, CRNP, Kelly Gebo, MD, Cindy Voss, MA.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1**  
Demographic and Clinical Characteristics of Nonperinatally HIV-Infected Youth (Aged 12–24 Years) at Presentation to Care at HIVRN Sites (2002–2010)

	No. (%)										P Value
	2002 (n = 107)	2003 (n = 105)	2004 (n = 124)	2005 (n = 136)	2006 (n = 117)	2007 (n = 195)	2008 (n = 222)	2009 (n = 234)	2010 (n = 257)	Total (n = 1497)	
Age at presentation, y, median (IQR)	21 (19–23)	22 (15–23)	22 (20–23)	21 (19–23)	22 (20–23)	21 (19–23)	21 (20–23)	21 (20–23)	21 (19–23)	21 (20–23)	.39
Race/ethnicity											
Black	59 (55.1)	55 (52.4)	65 (52.4)	71 (52.2)	77 (65.8)	118 (60.5)	140 (63.1)	157 (67.1)	168 (65.4)	910 (60.8)	
White	22 (20.6)	21 (20.0)	30 (24.2)	21 (15.4)	17 (14.5)	30 (15.4)	38 (17.1)	38 (16.2)	36 (14.0)	253 (16.9)	.13
Hispanic	25 (23.4)	29 (27.6)	26 (30.0)	38 (28.0)	17 (14.5)	41 (21.0)	40 (18.0)	33 (14.1)	42 (16.3)	291 (19.4)	
Other/unknown	1 (0.9)	0	3 (2.4)	6 (4.4)	6 (5.1)	6 (3.1)	4 (1.8)	6 (2.6)	11 (4.3)	43 (2.9)	
Male	72 (67.3)	81 (77.1)	81 (65.3)	100 (73.5)	76 (73.5)	150 (76.9)	168 (75.7)	192 (82.0)	219 (85.2)	1149 (76.7)	<.001 <sup>a</sup>
HIV acquisition risk											
MSM	49 (45.8)	65 (61.9)	65 (52.4)	77 (56.6)	64 (54.7)	127 (65.1)	137 (61.7)	172 (73.5)	190 (73.9)	946 (63.2)	
HET	49 (45.8)	31 (29.5)	54 (43.5)	53 (39.0)	49 (41.9)	63 (32.3)	80 (36.0)	60 (25.6)	61 (23.7)	500 (33.4)	<.001 <sup>a</sup>
IDU	9 (8.4)	9 (8.6)	5 (4.0)	6 (4.4)	4 (3.4)	5 (2.6)	5 (2.3)	2 (0.9)	5 (1.9)	51 (3.4)	
CD4 count, cells/mm <sup>3</sup>											
<200	18 (16.8)	19 (18.1)	21 (16.9)	26 (19.1)	13 (11.1)	39 (20.0)	35 (15.8)	29 (12.4)	34 (13.2)	234 (15.6)	
200–<350	13 (12.1)	27 (25.7)	31 (25.0)	28 (20.6)	30 (25.6)	49 (25.1)	58 (26.1)	65 (27.8)	55 (21.4)	356 (23.8)	.14
350–<500	35 (32.7)	23 (21.9)	42 (33.9)	42 (30.9)	44 (37.6)	59 (30.3)	66 (29.7)	70 (29.9)	82 (31.9)	463 (30.9)	
500	41 (38.3)	36 (34.3)	30 (24.2)	40 (29.4)	30 (25.6)	48 (24.6)	63 (28.4)	70 (29.9)	86 (33.5)	444 (29.7)	
HIV-1 RNA, log <sub>10</sub> copies/mL											
2.6–<4.0	32 (29.9)	32 (30.5)	42 (33.9)	39 (28.7)	29 (24.8)	56 (28.7)	74 (33.3)	79 (33.8)	75 (29.2)	458 (30.6)	
4.0–<4.7	30 (28.0)	34 (32.4)	30 (24.2)	37 (27.2)	36 (30.8)	57 (29.2)	67 (30.2)	86 (36.8)	80 (31.1)	457 (30.5)	
4.7–<5.0	11 (10.3)	11 (10.5)	21 (16.9)	16 (11.8)	12 (10.3)	27 (13.8)	27 (12.2)	33 (14.1)	34 (13.2)	192 (12.8)	.001 <sup>a</sup>
5.0	27 (25.2)	22 (21.0)	26 (21.0)	27 (19.9)	37 (31.6)	51 (26.2)	50 (22.5)	28 (12.0)	58 (22.6)	326 (21.8)	
Missing	7 (6.5)	6 (5.7)	5 (4.0)	17 (12.5)	3 (2.6)	4 (2.0)	4 (1.8)	8 (3.4)	10 (3.9)	64 (4.3)	
Site of care											

	No. (%)										P Value
	2002 (n = 107)	2003 (n = 105)	2004 (n = 124)	2005 (n = 136)	2006 (n = 117)	2007 (n = 195)	2008 (n = 222)	2009 (n = 234)	2010 (n = 257)	Total (n = 1497)	
Pediatric	16 (14.9)	15 (14.3)	10 (8.1)	25 (18.4)	15 (12.8)	17 (8.7)	19 (8.6)	32 (13.7)	30 (11.7)	179 (12.0)	.09
Adult	91 (85.1)	90 (85.7)	114 (91.9)	111 (81.6)	102 (87.2)	178 (91.3)	203 (91.4)	202 (86.3)	227 (88.3)	1318 (88.0)	

Abbreviations: HET, heterosexual; HIV, human immunodeficiency virus; HIVRN, HIV Research Network; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men.

<sup>a</sup> Significant.

**Table 2**Factors Associated With CD4 Count Less Than 350 Cells/mm<sup>3</sup> at Presentation for Care to HIVRN Sites

Factor	Univariate OR (95% CI)	Multivariate <sup>a</sup> AOR (95% CI)
Race/ethnicity		
White	1 [Reference]	1.0 [Reference]
Black	1.22 (1.01–1.48) <sup>b</sup>	2.03 (1.31–3.15) <sup>b</sup>
Hispanic	1.12 (0.97–1.30)	1.69 (1.21–2.34) <sup>b</sup>
Male	1.60 (1.37–1.86) <sup>b</sup>	1.63 (1.16–2.30) <sup>b</sup>
Age at presentation	1.12 (1.07–1.16) <sup>b</sup>	1.14 (1.06–1.23) <sup>b</sup>
HIV acquisition risk		
MSM	1 [Reference]	1 [Reference]
HET	0.91 (0.80–1.03)	1.43 (1.08–1.88) <sup>b</sup>
IDU	0.51 (0.32–0.80) <sup>b</sup>	0.85 (0.41–1.76)
HIV-1 RNA, log <sub>10</sub> copies/mL		
2.6–<4.0	1 [Reference]	1 [Reference]
4.0–<4.7	1.95 (1.45–2.63) <sup>b</sup>	2.00 (1.54–2.59) <sup>b</sup>
4.7–<5.0	3.54 (2.50–5.02) <sup>b</sup>	3.78 (2.54–5.64) <sup>b</sup>
5.0	7.11 (5.61–9.00) <sup>b</sup>	8.40 (6.82–10.3) <sup>b</sup>
Missing	2.58 (1.21–5.50) <sup>b</sup>	2.50 (1.18–5.28) <sup>b</sup>

Abbreviations: AOR, adjusted odds ratio; HET, heterosexual; HIV, human immunodeficiency virus; HIVRN, HIV Research Network; IDU, injection drug use; MSM, men who have sex with men; OR, odds ratio.

<sup>a</sup> Multivariate logistic regression adjusted for year presented to care, gender, race/ethnicity, age at presentation, HIV acquisition risk, viral load, region, and site.

<sup>b</sup> Significant.

**Table 3**

Factors Associated With CD4 Count Less Than 350 Cells/mm<sup>3</sup> at Presentation for Care to HIVRN Sites:  
Subgroup Analysis of the 1149 Males in the HIVRN Cohort

Factor	Univariate OR (95% CI)	Multivariate <sup>a</sup> AOR (95% CI)
Race/ethnicity		
White	1 [Reference]	1 [Reference]
Black	1.36 (1.08–1.72) <sup>b</sup>	2.14 (1.25–3.64) <sup>b</sup>
Hispanic	1.08 (0.89–1.31)	1.75 (1.18–2.59) <sup>b</sup>
Age at presentation	1.11 (1.08–1.14) <sup>b</sup>	1.15 (1.08–1.22) <sup>b</sup>
HIV acquisition risk		
MSM	1 [Reference]	1 [Reference]
HET	1.53 (1.20–1.97) <sup>b</sup>	1.42 (1.04–1.94) <sup>b</sup>
IDU	0.58 (0.35–0.95) <sup>b</sup>	0.77 (0.39–1.51)
HIV-1 RNA, log <sub>10</sub> copies/mL		
2.6–<4.0	1 [Reference]	1 [Reference]
4.0–<4.7	2.00 (1.20–3.32) <sup>b</sup>	2.08 (1.27–3.41) <sup>b</sup>
4.7–<5.0	3.31 (2.24–4.89) <sup>b</sup>	3.61 (2.38–5.48) <sup>b</sup>
5.0	6.39 (4.44–9.21) <sup>b</sup>	7.63 (5.40–10.8) <sup>b</sup>
Missing	2.57 (1.38–4.77) <sup>b</sup>	2.29 (1.15–4.54) <sup>b</sup>

Abbreviations: AOR, adjusted odds ratio; HET, heterosexual; HIV, human immunodeficiency virus; HIVRN, HIV Research Network; IDU, injection drug use; MSM, men who have sex with men; OR, odds ratio.

<sup>a</sup>Subgroup analysis of males: multivariate logistic regression adjusted for year presented to care, race/ethnicity, HIV acquisition risk, age at enrollment, viral load, region, and site.

<sup>b</sup>Significant.